Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines (Q35953762)

11 August 2017

1 reference

title

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines (English)

1 reference

11 August 2017

Michael Vajdy

1

1 reference

11 August 2017

Indresh Srivastava

2

1 reference

11 August 2017

John Polo

3

1 reference

11 August 2017

John Donnelly

4

1 reference

11 August 2017

Derek O'Hagan

5

1 reference

11 August 2017

Manmohan Singh

6

1 reference

11 August 2017

1 December 2004

1 reference

Immunology & Cell Biology

11 August 2017

1 reference

11 August 2017

82

1 reference

11 August 2017

6

1 reference

11 August 2017

617-627

1 reference

Reverse vaccinology, a genome-based approach to vaccine development

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Modulating vaccine responses with dendritic cells and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Improving protein therapeutics with sustained-release formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Polymer-grafted starch microparticles for oral and nasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Immunological adjuvants: a role for liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

ISCOMs and other saponin based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Enhancing immune responses using suicidal DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Potential DNA vaccine integration into host cell genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Dendritic cells internalize vaccine adjuvant after intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Cationic microparticles: A potent delivery system for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Epithelial M cells: gateways for mucosal infection and immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

The role of nasopharyngeal lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Protection against vaginal SIV transmission with microencapsulated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

21 January 2018

HIV and mucosal immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

RNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Alphavirus vectors: development and potential therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Self-replicating Semliki Forest virus RNA as recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Alphavirus replicon particles as candidate HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

Action of Saponin on Biological Cell Membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2004.01288.X

10.1111/J.1440-1711.2004.01288.X

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b7ml5t4zs5bmbf5nbg7ydyvrde

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_b7ml5t4zs5bmbf5nbg7ydyvrde

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b7ml5t4zs5bmbf5nbg7ydyvrde

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/b7ml5t4zs5bmbf5nbg7ydyvrde